The SELUTION SLR™ drug-eluting balloon system for the treatment of symptomatic femoropopliteal lesions

Abstract

Endovascular treatment has become first line therapy for the treatment of femoropopliteal disease. Drug-coated devices play a key role in maintaining vessel patency. In the past antiproliferative coating of drug-coated balloons (DCBs) exclusively consisted of paclitaxel. Use of limus drugs was limited by a short residency time in the vessel wall. Besides the drug, the SELUTION SLR™ drug-eluting balloon system consists of a coating formulation of four excipients. The first excipient is a biodegradable polymer (poly(lactic-co-glycolic acid)) that is intermixed with the sirolimus to form micro-reservoirs and regulates drug release via matrix degradation. This review summarizes the existing pre-clinical and clinical literature on treatment of femoropopliteal artery lesions with the SELUTION SLR DCB.

Keywords: SELUTION SLR™; drug-coated balloon; drug-eluting balloon system; femoropopliteal artery; peripheral arterial occlusive disease; poly(lactic-co-glycolic acid) (PLGA); sirolimus; superficial femoral artery.